RAPID: Postoperative Pain, Recovery and Discharge Following Robot-assisted Laparoscopic Prostatectomy

Sponsor

Karolinska Institutet (Other)

Overall Status

Completed

CT.gov ID

NCT03639389

Collaborator

(none)

211

Enrollment

Locations

Arms

38.9

Actual Duration (Months)

105.5

Patients Per Site

2.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Prostate cancer is the commonest cancer form in men in Northern Europe. Management of the cancer often includes surgical removal of the primary tumor. In the last 5-10 years, robot assisted laparoscopic prostatectomy (RALP) has become common. Good pain relief is central to early mobilization and greater patient satisfaction. Randomized controlled studies on pain relief following RALP are few and the role of spinal analgesia in pain management following robotic surgery has not been described. Techniques available for pain relief following RALP include spinal anesthesia with or without opiates, intravenous analgesia with morphine or a multimodal pain management technique using a combination of several analgesics. Spinal anesthesia and analgesia reduces the surgical stress and inflammatory response following laparoscopic colorectal surgery and may offer similar benefit even during RALP.

Early perioperative complications may cause postoperative morbidity following robotic surgery, and sometimes delay home discharge. Since all robotic operations in the pelvic region are performed in a deep Trendelenberg position, this can even have negative consequences for the heart, brain and the lungs. Cardiac complications in the form of minimal cardiac injury or mild heart failure have not been previously studied following RALP. Additionally, patients are sometimes delirious in the early postoperative period following RALP. The precise cause for this remains unclear and may be related to pain, cognitive dysfunction or an urge to pass urine despite a urinary catheter.

In addition to good postoperative pain relief, early postoperative mobilization and home discharge are important milestones in recovery of full function following major surgery. With improvement in surgical technique, the time has come to evaluate if RALP can be performed on an ambulatory basis. The main aims of this study are:

Can RALP be performed on an ambulatory basis and patients ready to be discharged home at 8 pm?
To determine if spinal anesthesia reduces pre-discharge pain intensity, stress response and other perioperative side effects.
Is sufentanil or fentanyl the analgesic of choice when administered spinally together with bupivacaine as an analgesic.
To determine the frequency and severity of cardiac and respiratory complications in the steep Trendelenberg position during RALP.
To assess the quality of recovery, quality of life and activities of daily living following ambulatory RALP?

Condition or Disease	Intervention/Treatment	Phase
Radical Prostatectomy Postoperative Pain	Drug: Bupivacaine Drug: Analgesics	Phase 3

Detailed Description

Prospective, randomized study blinded to observers (spinal or no-spinal). All formal approvals will be obtained from different authorities prior to study start. It will be registered in an international database (clinicaltrials.gov).

Patients > 18 years, ASA I-III, undergoing RALP will be included into the study. Patients on chronic opiate medication, those with contraindications to spinal anesthesia or allergy to any component drugs used during spinal anesthesia or other analgesics used in the study will be excluded. Patients living alone or having no adult at home to look after them during the first 24 h after home discharge will also be excluded. Informed written consent will be obtained from all patients. On the morning of surgery, all patients will receive paracetamol 1 g orally 1 h before planned surgery, and will be randomized to one of two groups as shown below:

Robot-assisted laparoscopic prostatectomy (RALP) (morning surgery)

Group MM: This group of patients will not receive spinal anesthesia but have multimodal pain management including COX-2 blockers, pregabalin and oxycontin for pain management
Group SF (Spinal/Fentanyl): Spinal anesthesia with bupivacaine 12.5 mg+fentanyl 15 ug Robot-assisted laparoscopic prostatectomy (RALP) (afternoon surgery)
Group MM: This group of patients will not receive spinal anesthesia but have multimodal pain management including COX-2 blockers, pregabalin and oxycontin for pain management 2. Group SS (Spinal/Sufentanil): Spinal anesthesia with bupivacaine 12.5 mg+sufentanil 5 ug

Anesthesia will be standardized in all other aspects in all groups and basically include propofol for induction, rocuronium as muscle relaxant, sevoflurane and remifentanil for pain management and betamethasone + ondansetron as prophylaxis against post-operative nausea or vomiting (PONV). Surgery will also be standardized in all patients and follow the routines already established in the hospital.

At the end of surgery, patients will be transferred to the post-anesthesia care unit (PACU) where they will remain for 4 h observation and subsequently transferred to the general surgical wards for observation and discharge home. All measurement times will be taken from the end of surgery, which will be considered as t = 0.

The following parameters will be recorded:

Total morphine consumption during 0-4, 4-home discharge and analgesic supplements after home discharge and up to 1 week will be recorded. Time to first morphine administration after surgery will be registered.
Blood tests for measurement of cortisol, glucose, insulin, creatinine, NTproBNP and hsTnT will be taken at fixed time points before and after surgery.
Pain intensity will be registered using NRS after 1, 2, 3, 4 and every 4 h until home discharge, and thereafter every 24 h for 1 week.
All side effects (PONV, pruritus, respiratory depression, oxygen saturation and need for supplementary oxygen) and complications (bleeding, reoperation, pneumothorax etc.) will be recorded. Postoperative delirium will be assessed 0-2 h postoperatively. Prolonged PACU stay or re-admission to PACU will be registered. Clavien-Dindo classification for grade of complication will be registered as also Postoperative Morbidity score (POMS).
Respiratory function will be recorded in the following ways: blood gas (after 1 and 4 h), saturation, spirometry, maximum expiratory pressure preoperatively and after 4 h. Need for supplementary oxygen to maintain SpO2 > 93% will be registered.
Time to mobilization, time to discharge to the general ward (from PACU), "home readiness" (primary endpoint) and home discharge will be registered in accordance with standardized criteria. Criteria for home readiness: normal vital signs, pain intensity < 4 (NRS 0-10), minimal or no postoperative nausea or vomiting, able to sit, walk and go unhindered, no surgical complication (bleeding, fever), fully awake and able to follow instructions (normal cognition), normally functioning urinary catheter and an adult at home during the first 24 h after discharge home).
Quality of Recovery 15 (QoR 24) will be measured before home-discharge and after 24 h using a standardized questionnaire.
Quality of life will be measured preoperatively and after 7 and 30 days using the questionnaire EQ5D and WHODAS.

Study Design

Study Type:

Interventional

Actual Enrollment :

211 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Prospective, randomized, observer-blindedProspective, randomized, observer-blinded

Masking:

Single (Outcomes Assessor)

Masking Description:

Outcome observer blinded to method of analgesia (spinal/no-spinal)

Primary Purpose:

Treatment

Official Title:

Randomised Comparison Between Spinal/GA or GA Alone Following Robot-assisted Laparoscopic Prostatectomy. Stress Response, Pain, Recovery and Home Discharge

Actual Study Start Date :

Jan 1, 2019

Actual Primary Completion Date :

Mar 29, 2022

Actual Study Completion Date :

Mar 29, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Analgesics, multimodal Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics	Drug: Analgesics Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients Other Names: paracetamol + NSAID + morphine
Experimental: Bupivacaine Spinal anesthetic with bupivacain + fentanyl/sufentanil	Drug: Bupivacaine Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil Other Names: Marcain spinal

Arm

Intervention/Treatment

Active Comparator: Analgesics, multimodal

Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics

Drug: Analgesics

Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients

Other Names:

paracetamol + NSAID + morphine

Experimental: Bupivacaine

Spinal anesthetic with bupivacain + fentanyl/sufentanil

Drug: Bupivacaine

Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil

Other Names:

Marcain spinal

Outcome Measures

Primary Outcome Measures

Number of patients ready for home discharge at 8 pm after surgery [With 12 h of surgery start]
Number of patients ready to be discharged home after surgery when using a standardized home-discharge criteria

Secondary Outcome Measures

Pain intensity [7 days postoperatively]
Intensity of pain recorded using numeric rating score at defined time intervals postoperatively
Stress markers in plasma [24 hours]
Blood glucose, cortisol and insulin
Quality of Recovery [3 days postoperatively]
Quality of recovery will be measured at defined time intervals using a standardized questionnaire
Quality of life after surgery [30 days postoperatively]
Quality of life will be measured at defined time intervals pre- and postoperatively using a standardized questionnaire
Amount (mg) of morphine administered as rescue analgesic at 12 and at 24 h [At 12 hours and 24 hours postoperatively]
Total amount of rescue analgesics (morphine) administered to achieve good analgesia and mild pain (NRS < 4)